
Arthralgia Management Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The global arthralgia management market size was valued at USD 6.55 Billion in 2024 , driven by the emphasis on developing effective treatments to lower down arthritis cases across the globe. The market is expected to grow at a CAGR of 9.10 % during the forecast period of 2025-2034, with the values likely to rise USD 15.65 Billion by 2034 .
Arthralgia Management: Introduction
Arthralgia refers to pain and discomfort in one or multiple joints. It is not a disease, but a symptom of an underlying disease called arthritis. Arthritis causes joint inflammation, which in turn, can lead to joint pain and stiffness. Common areas of pain include hands, arms, shoulders, back, feet, knees, pelvis, and hip bones. Arthralgia can affect one’s ability to perform day to day activities and may interfere with the sleep cycle as well.
Arthralgia treatment constitutes pain relievers in the form of ointments or drugs, surgery and therapies like exercise, joint mobilization, acupuncture, and dietary supplements.
Global Arthralgia Management Market Analysis
Musculoskeletal symptoms like myalgia, arthralgia, backache, and generalized body ache are not commonly associated with coronavirus-related diseases like pneumonia, however, around 30% of the patients hospitalized with the coronavirus reported a musculoskeletal issue. Arthralgia was one of the most severely painful symptoms that coincided with other respiratory issues. Therefore, there has been a significant arthralgia management market growth during the historical period, especially during the COVID-19 pandemic.
Chronic pain is the key characteristic of arthralgia. Mild pain relievers, nonsteroidal anti-inflammatory drugs, corticosteroids are some of the most common treatments available. However, to combat more severe and persistent pains, researchers have been working on new technologies as well. For instance, nanotechnology-based drugs have shown positive results in pain control with limited side effects. Some nanotechnology-based tools can also help in accurate pain measurement, which can help with diagnostics and improve the efficiency of different treatments.
With a deeper understanding of pain inducing electric signals in the nervous system, there are new devices that work with a neuromodulation approach. Such devices include peripheral and spinal stimulators that treat complex pain syndromes by sending electrical impulses to reverse pathologic neural processes. Clinical evidence also supports the treatment. As we progress further into the future, new technologies are set to enter the market. This indicates that arthralgia management market value is likely to grow significantly in the coming years.
Global Arthralgia Management Market Segmentation
The Expert Market Research report titled “Global Arthralgia Management Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
With increasing rates of obesity and injury, arthritis cases are expected to rise globally. The prevalence of obesity among adults in the American region (north, central, and south) is predicted to reach around 47% to 49% by 2035 , affecting nearly half of the population. Similar trend is followed by the European region, where obesity is predicted to affect 35% of the women and 39% of the men . As obesity is a major cause of osteoarthritis, the demand for arthralgia management is expected to grow in the American and European region during the forecast period.
Arthritis is one of the most common diseases associated with an aging population. As the Asian region accounts for most of the world’s geriatric population, the arthralgia management market share is anticipated to observe an exponential growth in this territory as well, converse to the North America holding a big market share in the historical period.
Global Arthralgia Management Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Arthralgia Management: Introduction
Arthralgia refers to pain and discomfort in one or multiple joints. It is not a disease, but a symptom of an underlying disease called arthritis. Arthritis causes joint inflammation, which in turn, can lead to joint pain and stiffness. Common areas of pain include hands, arms, shoulders, back, feet, knees, pelvis, and hip bones. Arthralgia can affect one’s ability to perform day to day activities and may interfere with the sleep cycle as well.
Arthralgia treatment constitutes pain relievers in the form of ointments or drugs, surgery and therapies like exercise, joint mobilization, acupuncture, and dietary supplements.
Global Arthralgia Management Market Analysis
Musculoskeletal symptoms like myalgia, arthralgia, backache, and generalized body ache are not commonly associated with coronavirus-related diseases like pneumonia, however, around 30% of the patients hospitalized with the coronavirus reported a musculoskeletal issue. Arthralgia was one of the most severely painful symptoms that coincided with other respiratory issues. Therefore, there has been a significant arthralgia management market growth during the historical period, especially during the COVID-19 pandemic.
Chronic pain is the key characteristic of arthralgia. Mild pain relievers, nonsteroidal anti-inflammatory drugs, corticosteroids are some of the most common treatments available. However, to combat more severe and persistent pains, researchers have been working on new technologies as well. For instance, nanotechnology-based drugs have shown positive results in pain control with limited side effects. Some nanotechnology-based tools can also help in accurate pain measurement, which can help with diagnostics and improve the efficiency of different treatments.
With a deeper understanding of pain inducing electric signals in the nervous system, there are new devices that work with a neuromodulation approach. Such devices include peripheral and spinal stimulators that treat complex pain syndromes by sending electrical impulses to reverse pathologic neural processes. Clinical evidence also supports the treatment. As we progress further into the future, new technologies are set to enter the market. This indicates that arthralgia management market value is likely to grow significantly in the coming years.
Global Arthralgia Management Market Segmentation
The Expert Market Research report titled “Global Arthralgia Management Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
- Drug
- NSAIDs
- Corticosteroids
- Hyaluronic Acid Injection
- Other Drugs
- Knee and Ankle Pain
- Hip Pain
- Shoulder and Elbow Pain
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
With increasing rates of obesity and injury, arthritis cases are expected to rise globally. The prevalence of obesity among adults in the American region (north, central, and south) is predicted to reach around 47% to 49% by 2035 , affecting nearly half of the population. Similar trend is followed by the European region, where obesity is predicted to affect 35% of the women and 39% of the men . As obesity is a major cause of osteoarthritis, the demand for arthralgia management is expected to grow in the American and European region during the forecast period.
Arthritis is one of the most common diseases associated with an aging population. As the Asian region accounts for most of the world’s geriatric population, the arthralgia management market share is anticipated to observe an exponential growth in this territory as well, converse to the North America holding a big market share in the historical period.
Global Arthralgia Management Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Sanofi
- AstraZeneca
- Johnson & Johnson
- GlaxoSmithKline PLC (UK)
- Bayer AG
- Abbott
- Pfizer, Inc.
- Mylan N.V
- Teva Pharmaceuticals
- Novartis AG
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Arthralgia Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Arthralgia Epidemiology Analysis
- 5.1 Epidemiology Overview (2018-2034)
- 5.2 North America Arthralgia Epidemiology (2018-2034)
- 5.3 Europe Arthralgia Epidemiology (2018-2034)
- 5.4 Asia-Pacific Arthralgia Epidemiology (2018-2034)
- 5.5 Latin America Arthralgia Epidemiology (2018-2034)
- 5.6 Middle East & Africa Arthralgia Epidemiology (2018-2034)
- 6 Global Arthralgia Management Market Overview
- 6.1 Global Arthralgia Management Market Historical Value (2018-2024)
- 6.2 Global Arthralgia Management Market Forecast Value (2025-2034)
- 7 Global Arthralgia Management Market Landscape
- 7.1 Global Arthralgia Management: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Global Arthralgia Management: Product Landscape
- 7.2.1 Analysis by Type
- 7.2.2 Analysis by Diagnosis
- 7.2.3 Analysis by Application
- 8 Global Arthralgia Management Market Dynamics
- 8.1 Market Drivers and Constraints
- 8.2 SWOT Analysis
- 8.3 Porter’s Five Forces Model
- 8.4 Key Demand Indicators
- 8.5 Key Price Indicators
- 8.6 Industry Events, Initiatives, and Trends
- 8.7 Value Chain Analysis
- 9 Global Arthralgia Management Market Segmentation
- 9.1 Global Arthralgia Management Market by Drug Class
- 9.1.1 Market Overview
- 9.1.2 Drug
- 9.1.3 NSAIDs
- 9.1.4 Corticosteroids
- 9.1.5 Hyaluronic Acid Injection
- 9.1.6 Other Drugs
- 9.2 Global Arthralgia Management Market by Treatment
- 9.2.1 Market Overview
- 9.2.2 Knee and Ankle Pain
- 9.2.3 Hip Pain
- 9.2.4 Shoulder and Elbow Pain
- 9.2.5 Others
- 9.3 Global Arthralgia Management Market by Distribution Channel
- 9.3.1 Market Overview
- 9.3.2 Hospital Pharmacies
- 9.3.3 Retail Pharmacies
- 9.3.4 Online Pharmacies
- 9.4 Global Arthralgia Management Market by Region
- 9.4.1 Market Overview
- 9.4.2 North America
- 9.4.3 Europe
- 9.4.4 Asia Pacific
- 9.4.5 Latin America
- 9.4.6 Middle East and Africa
- 10 North America Arthralgia Management Market
- 10.1 Market Share by Country
- 10.2 United States of America
- 10.3 Canada
- 11 Europe Arthralgia Management Market
- 11.1 Market Share by Country
- 11.2 United Kingdom
- 11.3 Germany
- 11.4 France
- 11.5 Italy
- 11.6 Others
- 12 Asia Pacific Arthralgia Management Market
- 12.1 Market Share by Country
- 12.2 China
- 12.3 Japan
- 12.4 India
- 12.5 ASEAN
- 12.6 Australia
- 12.7 Others
- 13 Latin America Arthralgia Management Market
- 13.1 Market Share by Country
- 13.2 Brazil
- 13.3 Argentina
- 13.4 Mexico
- 13.5 Others
- 14 Middle East and Africa Arthralgia Management Market
- 14.1 Market Share by Country
- 14.2 Saudi Arabia
- 14.3 United Arab Emirates
- 14.4 Nigeria
- 14.5 South Africa
- 14.6 Others
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 INDIA CDSCO
- 15.1.4 JAPAN PMDA
- 15.1.5 Others
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnership and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 Sanofi
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 AstraZeneca
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 Johnson & Johnson
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 GlaxoSmithKline PLC (UK)
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Bayer AG
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Abbott
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 Pfizer, Inc.
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Mylan N.V
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 Teva Pharmaceuticals
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Novartis AG
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.